This variability suggests that BAP1 loss alone may not be sufficient to predict PITAC responsiveness, and other factors, such as tumor histology, immune microenvironment, or prior treatments, may contribute to the observed heterogeneity in outcomes [36]. This evidence concerns the gene BAP1 and neoplasm.